FIELD: chemistry.
SUBSTANCE: invention relates to biochemistry, in particular to an isolated monoclonal antibody or its antigen-binding fragment, which specifically binds to BCMA.
EFFECT: invention enables to obtain an antibody which effectively specifically binds to BCMA.
13 cl, 6 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO CSF-1R | 2020 |
|
RU2751249C1 |
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
